
Still relevant, still fighting... All You Fascists Written by Woody Guthrie c. 1942 Sung by Billy Bragg and Wilco youtu.be/dWBeGK96pVQ

I’d like to believe I leave this place a little less lonely, a little more just. - me. Immunology investor when I’m not fighting fascists.

Still relevant, still fighting... All You Fascists Written by Woody Guthrie c. 1942 Sung by Billy Bragg and Wilco youtu.be/dWBeGK96pVQ

Well said Matthew. If you're quoting Hitler in your newsletter, you are indeed a hate group.

“A majority” $PRTG @PortageBiotech
$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.

$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.
We’re pleased to share updated interim data on our lead #iNKT engager in a Phase 1/2 study for the treatment of #melanoma and #NSCLC at #ASCO23. For more details on the poster, click here: bit.ly/3qogjN0

$PRTG. @PortageBiotech We’ve been waiting a very long time for good news. The abstract certainly points to that. And while there were 2 CR, 1 PR, it’s the 10 SD. Is that something we’re gonna like? A lot? Hey Ian, would you host a q and a for investors after #ASCO?
$PRTG Ian walters CEO of portage is on this panel to discuss the next innovations in medicine and primarily the future of immuno-oncology (inkt ) right after there asco poster release on the 3rd June 😉 #ASCO23

$PRTG early stage in p1/p2 ,wont necessary see the press others receive,their abstract is worth a look Strong early efficacy results at low/mid dose in their inkt agonist treating nsclc stage 4. Patients had not repsonded to previous therapies and PD-1. meetings.asco.org/abstracts-…


To note stable disease(SD) in 10no lesion given this is stage 4 nsclc patients is equally as credible at their low dose (1-3mg) imm60 could be a tangible alternative to both chemo and or PEM . 12month progression free survival will be very telling $PRTG

$PRTG. It’s a big deal!!
$PRTG “well tolerated” “no MTD was determined” “2 lesions completely resolved” we can’t forget these patients have sadly been through several other treatments that failed. Well done @PortageBiotech you seem to be improving outcomes with PORT2 🙏 #ASCO23 #CancerResearch


Elmo had so much fun with the Haim sisters! @HAIMtheband, let Elmo know if you need a new member. "Elmo Haim" sounds pretty good to Elmo! Ha ha ha! ❤️

Take a listen and realise the potential of $PRTG. At this price it's the bargain of the century. ASCO is weeks away where the data will prove the investment.
Check out this episode of @molecule2markt podcast, featuring our CEO Ian Walters! Ian discusses his background in the industry, along with Portage’s business model and progress in the clinic. Learn more about what makes Portage unique here: https://t.co/a5828ZVeNJ


CA is poised to be the 4th largest economy in the world, has the highest GDP of any state, & the most small businesses in the U.S. At the @MilkenInstitute Global Conference, Governor @GavinNewsom highlighted CA's commitment to expanding freedom & economic opportunity for all.

$PRTG This is it! I know a number of investors have been waiting to see this. Coincides with the ASCO conference poster. We get solid update on IMM60 alone and in combo with Keytruda, I’ll be a very happy investor.
$PRTG Boom! Global trial site updated with June 5th start. This is running in parallel with the going p1/p2 uk arm of the trial. Data is coming ! And quick with 12 new trial locations in the US and spain. Merck collab is really kicking into action now $MRK

$PRTG to remind people who may not be familiar with how stacked this pipeline is with both blockbuster assets fully owned! Inkt PORT2&3(100% owned) adenosine PORT6&7 (100% owned) INT230-6 PORT 1 (8% owned) SAUG 1 -PORT 4 (70% owned) STing VLP - 5 (44% owned)